Topical minoxidil has been the standard first-line topical treatment for androgenetic alopecia (AGA) for decades, and it still disappoints a good number of people who try it. Response is uneven, only a small share of each dose is absorbed through the scalp, and the usual ethanol and propylene glycol vehicle can leave the scalp itchy, dry or inflamed. This review brings together what has been published on these problems and on one proposed answer: carrying minoxidil in phospholipid vesicles (liposomes) in an aqueous, low-solvent serum.

Several independent laboratory and animal studies report higher skin or pilosebaceous deposition of minoxidil from liposomal and related vesicular carriers than from conventional solutions. Those results are encouraging but not uniform, and methods for judging follicular targeting are still debated ^[8]. We found no controlled human trial of a liposomal minoxidil serum. Separately, oxidative stress and mitochondrial changes in dermal papilla cells give a reasonable biological case for pairing minoxidil with scalp-supportive ingredients.

We discuss how a liposomal serum such as the one being developed on the Lipoedge™ platform by WBCIL (West Bengal Chemical Industries Limited) could be built around these findings, which questions the development programme must answer, and how the story can be told honestly to B2B partners and to consumers.

Highlights

§  Minoxidil works, but response varies and the vehicle often causes irritation or allergy.

§  Follicles can act as a reservoir for particle-based carriers; particle size, massage and sebum all matter.

§  Preclinical studies suggest liposomal minoxidil can raise skin and pilosebaceous deposition; human efficacy data are lacking.

§  Antioxidant and barrier-supportive ingredients are sensible partners for minoxidil, but their hair-growth benefit in this setting is unproven.